BCL2 and prostate cancer: The hnRNP L was shown to activate MAPK signaling while inhibiting caspase-3, -6 and -9 in bladder cancer cells as well as to suppress p53 expression and bcl-2/caspase-9/3 signaling via TP53 mRNA and bcl-2 binding, respectively, in prostate cancer cells (Lv et al., 2017; Zhou et al., 2017).